603676.SH
卫信康
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.14
−2.04%Year over year
Reported trailing growth
- Revenue
- -9.1%
- EBITDA
- —
- EBIT
- -10.7%
- EPS
- -8.7%
- Free cash flow
- -43.2%
- Operating cash flow
- -27.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -6.7%
- EBITDA
- +18.9%
- EBIT
- +21.5%
- Net income
- +9.6%
- EPS
- +9.6%
- Free cash flow
- -15.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026